Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cingulate stock

Learn how to easily invest in Cingulate stock.

Cingulate Inc. Common Stock is a biotechnology business based in the US. Cingulate shares (CING) are listed on the NASDAQ and all prices are listed in US Dollars. Cingulate employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Cingulate

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CING – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cingulate stock price (NASDAQ: CING)

Use our graph to track the performance of CING stocks over time.

Cingulate shares at a glance

Information last updated 2022-01-17.
Latest market close$2.60
52-week range$2.20 - $5.15
50-day moving average $2.82
200-day moving average $2.82
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.73

Buy Cingulate shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
$125 - $625
Open and fund an account with $25,000 - $250,000+

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cingulate stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cingulate price performance over time

Historical closes compared with the close of $2.6 from 2022-01-14

1 week (2022-01-10) 6.34%
1 month (2021-12-17) 0.39%
3 months (2021-10-14) N/A
6 months (2021-07-14) N/A
1 year (2021-01-14) N/A
2 years (2020-01-14) N/A
3 years (2019-01-14) N/A
5 years (2017-01-14) N/A

Cingulate financials

Gross profit TTM $-5,093,277
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value $0.28
Market capitalisation $29.4 million

TTM: trailing 12 months

Cingulate share dividends

We're not expecting Cingulate to pay a dividend over the next 12 months.

You may also wish to consider:

Cingulate overview

Cingulate Inc. , a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey. .

Frequently asked questions

What percentage of Cingulate is owned by insiders or institutions?
Currently 29.518% of Cingulate shares are held by insiders and 7.836% by institutions.
How many people work for Cingulate?
Latest data suggests 13 work at Cingulate.
When does the fiscal year end for Cingulate?
Cingulate's fiscal year ends in December.
Where is Cingulate based?
Cingulate's address is: 1901 West 47th Place, Kansas City, KS, United States, 66205
What is Cingulate's ISIN number?
Cingulate's international securities identification number is: US17248W1053

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site